Clostridium News and Research

RSS

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.

2 Nov 2010

University of Padua Professor wins Paul Ehrlich and Ludwig Darmstaedter Prize

Frankfurt am Main. The chemist and biologist Professor Cesare Montecucco, 62, of the Department of Biomedical Research at the University of Padua, Italy, has won the 100,000 euro Paul Ehrlich and Ludwig Darmstaedter Prize 2011 for his contribution to research in the field of bacterial diseases, including tetanus, botulism, anthrax and Helicobacter pylori associated diseases.

27 Oct 2010

Optimer presents two fidaxomicin Phase 3 trials data for CDI infection at IDSA Annual Meeting

Optimer Pharmaceuticals, Inc. announced today the presentation of combined data from its two fidaxomicin Phase 3 trials in patients with Clostridium difficile infection (CDI) at the 48th Annual Meeting of the Infectious Disease Society of America (IDSA) in Vancouver, British Columbia, Canada.

25 Oct 2010

ACG 75th Scientific Meeting to review advances in gastrointestinal research, treatment of digestive diseases

Many of the world's preeminent gastroenterologists will gather for the American College of Gastroenterology's (ACG) 75th Annual Scientific Meeting at the Henry B. Gonzalez Convention Center in San Antonio, Texas starting Monday October 18, 2010, to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

19 Oct 2010

Researchers explore impact of various factors on increasing rates of Clostridium difficile infection

In five different studies presented at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, researchers explored the impact of various factors on increasing rates of Clostridium difficile infection (C. difficile), such as the use of proton pump inhibitors (PPIs) and the substantial increase in antibiotic use due to new National Hospital Quality Measures; strategies to combat high rates of C. difficile infections; and cutting‐edge treatments for this potentially deadly-and quite common-infection.

19 Oct 2010

Cubist third quarter total net revenues increase 13% to $162.1M

Cubist Pharmaceuticals, Inc. today announced results for the third quarter ended September 30, 2010.

15 Oct 2010

Auxilium receives USPTO patent for XIAFLEX product

Auxilium Pharmaceuticals, Inc. a specialty biopharmaceutical company, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 7,811,560 claiming, among other things, purified collagenase, the active component in Auxilium's product XIAFLEX (collagenase clostridium histolyticum).

13 Oct 2010

FDA files complaint for permanent injunction against Brooklyn Juice Company

At the request of the U.S. Food and Drug Administration, the U.S. Department of Justice today filed a complaint for permanent injunction against a Brooklyn juice company to prevent it from processing and distributing juice products.

8 Oct 2010

Progenics receives NIH grant to develop novel monoclonal antibodies to treat C. difficile infection

Progenics Pharmaceuticals, Inc. today announced the award of a grant totaling $4,143,652 from the National Institutes of Health (NIH) for Progenics' program to develop novel monoclonal antibodies to treat Clostridium difficile (C. difficile) infection.

7 Oct 2010

New method for detecting spores of non-proteolytic Clostridium botulinum

The Institute of Food Research has collaborated in the development of a new method for detecting spores of non-proteolytic Clostridium botulinum. This bacterium is the major health hazard associated with refrigerated convenience foods, and these developments give the food industry and regulators more quantitative information on which to base the procedures that ensure food safety.

1 Oct 2010

Health Canada approves Meridian Bioscience's illumigene C. difficile molecular amplification assay

Meridian Bioscience, Inc., today announced that it has received an approved medical device license from Health Canada for its new molecular amplification assay, illumigene C. difficile. Clostridium difficile is a bacterium that can cause diarrhea and, in severe cases, a life-threatening inflammation of the colon.

1 Oct 2010

AJMS journal provides research update on new infectious pathogens

Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.

24 Sep 2010

Doctors misuse antibiotics to treat patients with respiratory tract infections: Study

Doctors frequently misuse antibiotics when treating patients hospitalized with respiratory tract infections (RTIs), according to a study to be published in the November issue of Infection Control and Hospital Epidemiology.

23 Sep 2010

Optimer submits fidaxomicin rolling NDA for treatment of Clostridium difficile infection

Optimer Pharmaceuticals, Inc. today announced that it has submitted the first section of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fidaxomicin to treat patients with Clostridium difficile infection (CDI) and to prevent recurrences of CDI. Optimer anticipates completing the submission in the fourth quarter of 2010 and plans to request priority review, which, if granted, could lead to an FDA decision on the NDA in the second quarter of 2011.

21 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

Optimer Pharmaceuticals to present fidaxomicin Phase 3 clinical trial data at ICAAC Conference

Optimer Pharmaceuticals, Inc. announced the presentation of new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston.

15 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Scientists find low levels of bacteria in fields sprayed with swine manure

That swine manure sprayed on to fields adds valuable nutrients to the soil is well known. But what is not known is whether all that manure is bringing harmful bacteria with it.

13 Sep 2010

Death and disability toll due to C. diff bacteria needs to be addressed

Almost 12,000 people died in alcohol-related vehicle crashes in 2008. About 15,000 Americans died of AIDS-related illness the same year. Both of these preventable causes of death have been the subject of massive, expensive and high-profile interventions by federal and state authorities. CRE encourages expenditures for these programs but the public health community should be even more concerned for greater society-wide risks.

10 Sep 2010

Mandatory disclosure makes hospitals work harder to prevent infections

Dr. Betsy McCaughey, Founder/ Chairman of the Committee to Reduce Infection Deaths (RID) said that "the 2009 New York State Department of Health Hospital Acquired Infections Report (released 9/1/2010) shows that mandatory disclosure saves lives by making hospitals work harder to prevent infections. Statewide rates decreased for nearly every type of infection measured. None increased."

3 Sep 2010